This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Comparative effectiveness of the different components of care provided in heart failure clinics-protocol for a systematic review and network meta-analysis.
Systematic reviews · 2019
Latest funding
- $436,050
Understanding the shifting landscape of Hepatitis B treatment in Canada
CIHR · 2026 · Principal investigator
- $393,753
The Response of Provincial Health Systems to COVID-19: Service Provision and Costs Across Health Sectors, First Nations and other populations
CIHR · 2020 · Co-investigator
- $680,085
New Drug and Technology Assessment in Bladder Cancer: Creation of a Novel Canadian Policy Model for Bladder Cancer
CIHR · 2020 · Co-investigator
1 publications.
Comparative effectiveness of the different components of care provided in heart failure clinics-protocol for a systematic review and network meta-analysis.
Slater M, Bielecki J, Alba AC, Abrahamyan L, Tomlinson G, Mak S, MacIver J, Zieroth S, Lee D, Wong W, Krahn M, Ross H, Rac VE
Understanding the shifting landscape of Hepatitis B treatment in Canada
Principal investigators: Tadrous, Mina; Mendlowitz, Andrew B; Wong, William Wai Lun
Keywords: Drugs; Health Outcomes; Health Policy; Hepatitis B; Pharmaceutical; Pharmacoequity
The Response of Provincial Health Systems to COVID-19: Service Provision and Costs Across Health Sectors, First Nations and other populations
Principal investigators: Krahn, Murray D; Kulkarni, Girish S
Keywords: Access To Health Care; Cost; Cost Effectiveness Analysis; Covid-19; Equity; First Nations; Indigenous Health; Quality Indicators; Regional Variation; Resource Use
New Drug and Technology Assessment in Bladder Cancer: Creation of a Novel Canadian Policy Model for Bladder Cancer
Principal investigators: Kulkarni, Girish S; Krahn, Murray D
Keywords: Bladder Cancer; Cost-Effectiveness; Policy; Population Data; Technology; Therapy
The Epidemiology and Economic Burden of Hepatitis C Viral infection in the First Nations Population in Ontario
Principal investigators: Krahn, Murray D; Walker, Jennifer
Keywords: Administrative Data; Costs And Cost Analysis; Epidemiology; Hepatitis C Virus
Real-world effectiveness and cost-effectiveness of novel hepatitis C treatments
Principal investigators: Tadrous, Mina; Antoniou, Tony; Wong, William Wai Lun
Keywords: Cost-Effectiveness; Drug Policy; Health Policy; Hepatitis C; Real-World Evidence
Testing, Reaching the Undiagnosed and Linkages to Care: "REACHing" for Impact
Principal investigators: Rourke, Sean B; Jones, Jennifer E; Monteith, Kenneth M; Proctor-Simms, Michelle; Tharao, Wangari E; Anis, Aslam H; Gahagan, Jacqueline C; Ibanez-Carrasco, Francisco; Janjua, Naveed Z; Kelly, Deborah V; Kim, John E; King, Alexandra; Krajden, Mel; Lachowsky, Nathan J; Otis, Joanne; Pai, Nitika; Thavorn, Kednapa; Worthington, Catherine A
Keywords: Biomedical And Clinical Team Grant
New Drug and Technology Assessment in Bladder Cancer: Creation of a Novel Canadian Policy Model for Bladder Cancer
Principal investigators: Kulkarni, Girish S; Krahn, Murray D
Keywords: Bladder Cancer; Cost-Effectiveness; Policy; Population Data
Understanding the treatment benefits of novel antiviral agents for hepatitis C: quality of life, health utility, cost, and return to work
Principal investigators: Wong, William Wai Lun; Krahn, Murray D
Keywords: Cost-Effectiveness; Direct-Acting Antiviral Therapies; Hepatitis C; Out-Of-Pocket Costs; Preferences; Quality Of Life; Time Costs; Utility
Cross sectional and longitudinal measures of quality of life and utility among patients with chronic hepatitis C virus infection
Principal investigators: Wong, William Wai Lun; Krahn, Murray D
Keywords: Cost-Effectivenss; Direct-Acting Antiviral Therapies; Hepatitis C; Out-Of-Pocket Costs; Preferences; Quality Of Life; Time Costs; Utility
A pharmacoeconomic policy model for hepatitis C: development and applications
Principal investigators: Thein, Hla Hla
Keywords: Antiviral Therapy; Burden Of Disease; Cost-Effectiveness Analysis; Economic Evaluation; Genetics; Health Policy; Hepatitis C Virus (Hcv); Personalised Medicine; Pharmacoeconomics; Transmission Modelling
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Medicine
- Biostatistics Division
- Medicine/Cardiology
- Institute of Health Policy, Management and Evaluation
- Toronto General Research Institute
- School of Pharmacy
- Other
Co-authors at University of Toronto, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
George Tomlinson
Biostatistics Division
1 shared papers, latest 2019
Jane Maciver
Institute of Health Policy, Management and Evaluation
1 shared papers, latest 2019
Lusine Abrahamyan
Faculty
1 shared papers, latest 2019
William Wong
School of Pharmacy
1 shared papers, latest 2019
Murray Krahn
Toronto General Research Institute
1 shared papers, latest 2019
Heather Ross
Medicine/Cardiology
1 shared papers, latest 2019
Douglas Lee
Medicine
1 shared papers, latest 2019
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.